Literature DB >> 32735639

What is the future of immunotherapy in multiple myeloma?

Leo Rasche1,2, Michael Hudecek1, Hermann Einsele1.   

Abstract

The treatment of multiple myeloma (MM) is currently being redefined by humoral and cellular immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy as a result of the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation. Today, monoclonal antibodies comprise the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most potent single agents for MM treatment. Herein, we present our assessment of and vision for MM immunotherapy in the short and midterm.
© 2020 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32735639     DOI： 10.1182/blood.2019004176

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.

Authors:  Vanessa Desantis; Francesco Domenico Savino; Antonietta Scaringella; Maria Assunta Potenza; Carmela Nacci; Maria Antonia Frassanito; Angelo Vacca; Monica Montagnani
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

Review 2.  Immuno-Imaging (PET/SPECT)-Quo Vadis?

Authors:  Carsten S Kramer; Antonia Dimitrakopoulou-Strauss
Journal:  Molecules       Date:  2022-05-23       Impact factor: 4.927

3.  Integrative analysis identifies CXCL11 as an immune-related prognostic biomarker correlated with cell proliferation and immune infiltration in multiple myeloma microenvironment.

Authors:  Huizhong Wang; Ruonan Shao; Wenjian Liu; Shumei Peng; Shenrui Bai; Bibo Fu; Congling Zhao; Yue Lu
Journal:  Cancer Cell Int       Date:  2022-05-14       Impact factor: 6.429

4.  Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM.

Authors:  Marietta S Truger; Johannes Duell; Xiang Zhou; Larissa Heimeshoff; Anna Ruckdeschel; Mara John; Angela Riedel; Sebastian Hüper; Jessica Peter; Wencke Walter; Larissa Haertle; Manja Meggendorfer; Max S Topp; Andreas Rosenwald; Matteo Claudio Da Via; Niccolo Bolli; Niels Weinhold; Hermann Einsele; Claudia Haferlach; K Martin Kortüm; Leo Rasche
Journal:  Blood Adv       Date:  2021-10-12

Review 5.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 6.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

7.  Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.

Authors:  Julia Dahlhoff; Hannah Manz; Tim Steinfatt; Julia Delgado-Tascon; Elena Seebacher; Theresa Schneider; Amy Wilnit; Zeinab Mokhtari; Paula Tabares; David Böckle; Leo Rasche; K Martin Kortüm; Manfred B Lutz; Hermann Einsele; Andreas Brandl; Andreas Beilhack
Journal:  Leukemia       Date:  2021-09-28       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.